title: Prophylactic immunosuppression with anti-interleukin-2 receptor monoclonal antibody LO-Tact-1 versus OKT3 in liver allografting. A two-year follow-up study.
abstract: A prospective trial was conducted in 129 recipients of primary liver transplantation, to compare induction immunosuppression using triple drug therapy (cyclosporine, steroids, and azathioprine; group 1, n = 42), versus triple drug therapy with a 10-day course of OKT3 (group 2, n = 44) or of the anti-interleukin-2 receptor monoclonal antibody LO-Tact-1 (group 3, n = 43). Two-year actual patient survival rates were 64%, 79%, and 93% in groups 1, 2, and 3, respectively (1 vs. 2, NS; I vs. III, P = 0.003; 2 vs. 3, NS). Up to 2 years after transplantation, 18%, 44%, and 53% of the grafts in groups 1, 2, and 3, respectively, had not experienced steroid-resistant acute rejection (1 vs. 2, P = 0.002; 1 vs. 3, P = 0.007; 2 vs. 3, NS). The overall incidence of chronic rejection was 4%. OKT3 therapy, but not LO-Tact-1, significantly increased the incidence of cytomegalovirus infections (P = 0.019). In conclusion, immunoprophylaxis with LO-Tact-1 seemed to provide a liver graft acceptance rate at least as satisfactory as that with OKT3, without an increase in the incidence of infections.
authors.affiliation: Department of Surgery, University of Louvain Medical School, Brussels, Belgium.
authors.forename: R
authors.initials: R
authors.lastname: Reding
authors.forename: A
authors.initials: A
authors.lastname: Feyaerts
authors.forename: H
authors.initials: H
authors.lastname: Vraux
authors.forename: D
authors.initials: D
authors.lastname: Latinne
authors.forename: B
authors.initials: B
authors.lastname: De La Parra
authors.forename: A
authors.initials: A
authors.lastname: Cornet
authors.forename: F
authors.initials: F
authors.lastname: Cormont
authors.forename: J
authors.initials: J
authors.lastname: Jamart
authors.forename: E
authors.initials: E
authors.lastname: Sokal
authors.forename: J
authors.initials: J
authors.lastname: de Ville de Goyet
authors.forename: J
authors.initials: J
authors.lastname: Lerut
authors.forename: H
authors.initials: H
authors.lastname: Bazin
authors.forename: J B
authors.initials: JB
authors.lastname: Otte
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003141:Communicable Diseases / Q000150:complications; D005500:Follow-Up Studies; D006084:Graft Rejection; D006801:Humans; D016867:Immunocompromised Host; D007165:Immunosuppression Therapy / Q000379:methods*; D016031:Liver Transplantation / Q000276:immunology*; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D011446:Prospective Studies; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D016853:Muromonab-CD3; D015375:Receptors, Interleukin-2